Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Boris Dominik Juelg · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2024 · $715,267 — Project 2: Summary While traditionally regarded as a generalized tolerogenic state, emerging data suggest that pregnancy is far from a simple anti-inflammatory shift but is characterized by dramatic shifts from inflammation to tolerance over the course of pregnancy, to accommodate changes in the …
Leonidas Stamatatos · FRED HUTCHINSON CANCER CENTER · 2024 · $800,602 — ABSTRACT PROJECT ONE We have reported on the design of a germline-targeting recombinant (rec) HIV-1 Env-derived immunogen, 426c.Mod.Core-C4b, that activates naïve B cells that express germline VRC01-class BCRs and on “booster” rec protein immunogen, HxB2.WT.Core-C4b, that improves the maturation of …
Sean PJ Whelan · WASHINGTON UNIVERSITY · 2024 · $6,793,772 — SUMMARY. The long term goals of Project 3 of the Respiro, Rubula, Peribunya, Phenui (R2P2) ReVAMPP are to use a prototype pathogen approach to identify and validate generalizable vaccine strategies against peribunyaviruses, and advance therapeutically useful monoclonal antibodies (mAb). To achieve t…
JOSEPH M FOX · UNIVERSITY OF DELAWARE · 2024 · $1,343,022 — Project Summary Administrative Core This Phase II COBRE will continue our center’s work to develop molecular approaches for probing biology, to discover and apply new chemical biology tools for the study of biological pathways associated with disease, and to develop computational approaches for …
MARK LEWIS · BIOQUAL, INC. · 2024 · $849,354 — The development of effective HIV vaccines and other prevention strategies relies on the use of nonhuman primates (NHPs) in preclinical studies. To meet this need, the Simian Vaccine Evaluation Units (SVEUs) provide NHP resources that primarily support preclinical evaluation of AIDS vaccines and prev…
KATERINA ANDRIANOVA · FLAG BIO, INC. · 2024 · $594,566 — The contractor will develop mRNAFlag as a vaccine adjuvant. mRNAFlag is an mRNA transcript that encodes for the deimmunized TLR5 agonist GP532. mRNAFlag would be developed within the context of an influenza mRNA vaccine, using an A/California/07/2009(H1N1) hemagglutinin in an LNP formulation used …
Alexander Bukreyev · VANDERBILT UNIVERSITY MEDICAL CENTER · 2024 · $2,727,988 — PROJECT SUMMARY – RP3 RNA vaccines are one of the most promising vaccine platforms available to rapidly deploy in response to emerging viral infections with pandemic potential. However, mechanistic investigations of how various mRNA vaccine approaches induce protective immune responses are warranted…
ROBERT H CARNAHAN · VANDERBILT UNIVERSITY MEDICAL CENTER · 2024 · $7,023,024 — PROJECT SUMMARY - RP5 Arenaviruses, a family of viruses with pandemic potential, can cause hemorrhagic fever, meningitis, and other clinical syndromes. These viruses include highly pathogenic strains such as Lassa virus (LASV) and Junín virus (JUNV), as well as less pathogenic strains like lymphocyt…
Anne Moscona · WASHINGTON UNIVERSITY · 2024 · $5,035,895 — Human parainfluenza virus type 3 (HPIV3) is the P1-Respiroviruses prototype for advancement of vaccines and therapeutic antibodies against respiroviruses due to the advanced state of knowledge of structure and function of the viral surface proteins: HN (receptor-binding protein; hemagglutinin-neuram…
Evan Alexander Scott · NORTHWESTERN UNIVERSITY AT CHICAGO · 2024 · $203,091 — SUMMARY-BIOMEDICAL RESOURCE CORE A major unmet challenge in kidney research is the inability of most traditional approaches and methods to harness the complexity of tissue function, structure, and cellular phenotypes. Innovations in nanotechnology provide powerful tools, reagents, and platforms that…
Lauren Carter · UNIVERSITY OF WASHINGTON · 2024 · $5,637,003 — PROJECT SUMMARY – CORE C: VACCINE PRODUCTION AND PROCESS DEVELOPMENT The Vaccine Production and Process Development Core will provide both high-throughput and scalable biologics production and characterization as well as comprehensive process development to support protein- and mRNA-based vaccine de…
Aaron Gregory Schmidt · WASHINGTON UNIVERSITY · 2024 · $4,728,047 — SUMMARY Emerging and re-emerging arthropod-vectored viruses pose a significant threat to human health. Tick- and mosquito-transmitted viruses can cause encephalitis and hemorrhagic fever leading to significant morbidity and mortality. West Nile virus (WNV), tick-borne encephalitis virus (TBEV), and …
Sallie R. Permar · WEILL MEDICAL COLL OF CORNELL UNIV · 2024 · $307,383 — ABSTRACT – PROJECT 3 Congenital cytomegalovirus (cCMV) is the most common in utero infection, affecting approximately 1 in every 200 newborns and causing devastating neurologic impairment in 1 in 5 infected infants. Placental transmission of CMV is significantly reduced in women experiencing reinfec…
Boris Dominik Juelg · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2024 · $600,000 — Project 2: Summary While traditionally regarded as a generalized tolerogenic state, emerging data suggest that pregnancy is far from a simple anti-inflammatory shift but is characterized by dramatic shifts from inflammation to tolerance over the course of pregnancy, to accommodate changes in the …
Clayton C Caswell · VIRGINIA POLYTECHNIC INST AND ST UNIV · 2024 · $195,342 — Project Summary Brucella spp. are bacteria that naturally infect a variety of domesticated and wild animals leading to abortions and sterility, and these bacteria are also capable of causing debilitating human infections, which often result from human exposure to infected animals and animal product…
Rosemarie Mason · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $1,317,404 — This project is part of a systematic Nipah virus (NiV) program aimed at evaluating a candidate NiV vaccine (mRNA-1215) that has advanced to a Phase I clinical trial (study VRC322). We conducted a pilot study (study VRC-22-0989) in African Green Monkeys (AGM) to demonstrate that the mRNA-1215 vaccine…
DEBORAH M HINTON · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2024 · $395,674 — Nearly all virulence factors in Bordetella pertussis are activated by a master two-component system, BvgAS, composed of the sensor kinase BvgS and the response regulator BvgA. When BvgS is active, BvgA is phosphorylated (BvgAP), and virulence activated genes are expressed (the Bvg+ mode). When Bvg…
Corey Casper · FRED HUTCHINSON CANCER CENTER · 2024 · $126,171 — Abstract Scientific Core One has the responsibility of creating, validating, and providing R&D-grade HIV-Env immunogen-expressing self-amplifying RNAs (saRNAs) complexed with the nanostructured lipid carrier (NLC) delivery vehicle to project leads at Fred Hutchinson Cancer Research Center for in viv…
NATALIA ALEKSANDR OSNA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · 2024 · $241,763 — This project is a part of a P50 grant on exposome and alcohol. It is focused on understanding the innate immunity mechanisms, by which environmental exposure to ethanol metabolites increases the levels of hepatitis B viral (HBV) infection and promotes its persistence and liver injury. Despite a prop…
Jordan Green · JOHNS HOPKINS UNIVERSITY · 2024 · $284,285 — TR&D2 Abstract The goal of TR&D #2 is to bioengineer nanoimmunomaterial tools (NIMs) through the design and synthesis of new biomaterials and nanoparticles (NPs) created for immunomodulation. This TR&D is driven by the needs of CPs and SPs for safe, effective, and targeted tools to genetically manip…